| Baljeet S Uppal, MD | |
|
15405 N 99th Ave Ste B, Sun City, AZ 85351 | |
| (888) 553-8346 | |
| (623) 404-4530 |
| Full Name | Baljeet S Uppal |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 31 Years |
| Location | 15405 N 99th Ave Ste B, Sun City, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689898165 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | 49616 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Estrella Medical Center | Phoenix, AZ | Hospital |
| Banner Boswell Medical Center | Sun city, AZ | Hospital |
| Abrazo West Campus | Goodyear, AZ | Hospital |
| Chandler Regional Medical Center | Chandler, AZ | Hospital |
| Banner Del E. Webb Medical Center | Sun city west, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pinnacle Vein And Vascular Center Pllc | 8628338852 | 2 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
| Entity Name | Kenneth O Anaeme Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033270723 PECOS PAC ID: 6103968060 Enrollment ID: O20100115000378 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
| Entity Name | Cardiac Cath Lab Of Phoenix, Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841650850 PECOS PAC ID: 9133412653 Enrollment ID: O20160721000901 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
| Entity Name | Nhc Arizona Professional Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164970968 PECOS PAC ID: 5395005805 Enrollment ID: O20180201000357 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
| Entity Name | Pinnacle Vein And Vascular Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902312317 PECOS PAC ID: 8628338852 Enrollment ID: O20180208002604 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
| Entity Name | Arizona Foot And Ankle Medical Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427511872 PECOS PAC ID: 8123351277 Enrollment ID: O20190605001594 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
| Entity Name | Titan Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487281770 PECOS PAC ID: 9133540164 Enrollment ID: O20200529002753 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Baljeet S Uppal, MD 9744 W Bell Rd Ste A, Sun City, AZ 85351-1343 Ph: (888) 553-8346 | Baljeet S Uppal, MD 15405 N 99th Ave Ste B, Sun City, AZ 85351 Ph: (888) 553-8346 |
News Archive
Researchers at the Arizona Arthritis Center at the University of Arizona College of Medicine are investigating the effect of early interventions in the treatment of osteoarthritis, a condition currently affecting tens of thousands of Tucsonans.
New research from UC Davis Cancer Center has found that whether a person gets screened for colon cancer often depends on where they live in addition to their race or ethnicity.
Researchers have studied the effects of too much social networking among young girls and found that it is ruining their girlhood. The new Stanford University study looks at data from girls between the ages of 8 and 12 who spend "considerable" time using social media and finds that they are likely to be "less happy" than their unplugged peers.
Doctors and nurses in Victoria will be given Apple iPads as part of a trial to improve internet access in Victorian hospitals. According to Health Minister Daniel Andrews' announcement yesterday, 500 iPads would be sent to graduate doctors and nurses in January and if the $500,000 pilot program goes well, the devices could be used more widely.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
› Verified 7 days ago
Ramesh C. Patri, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 10404 W Coggins, Ste 107, Sun City, AZ 85351 Phone: 623-977-3335 Fax: 623-832-8413 | |
Dr. Richard Gittings Parry, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 10602 W Cameo Dr, Sun City, AZ 85351 Phone: 623-875-9006 | |
Dr. Louis Anthony Privitera, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 13203 N 103rd Ave, Suite J3, Sun City, AZ 85351 Phone: 623-583-7321 Fax: 623-583-7242 | |
Paravasthu S Ramanujam, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 10503 W Thunderbird Blvd, Suite 114, Sun City, AZ 85351 Phone: 623-875-7330 Fax: 623-875-7334 | |
John D Pyeatt, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 13041 N Del Webb Blvd, Sun City, AZ 85351 Phone: 623-977-7201 | |
Dr. Alfonso G. Ballesteros, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 14416 W Meeker Blvd Ste 100, Sun City, AZ 85375 Phone: 623-285-2780 Fax: 623-285-2728 |